Service hotline
86-571-87377955
Zhejiang Hospital, Lingyin Branch
Address：No. 12 Ling yin Road, Hangzhou 310013,Zhejiang, China
Email：zjyyhz@126.com
Zhejiang Hospital, Sandun Branch
Address：No. 1229 Gudun Road, Hangzhou 310030, Zhejiang, China
Email：zjyyhz@126.com
Home >News Center > Notifications
Recruiting | Patients with benign prostatic hyperplasia are invited to participate in this project
Hits: 3079 Time: 2021-05-26
If you are diagnosed with benign prostatic
hyperplasia, look at it quickly. This project may be suitable for you! At
present, the urology department of our hospital is carrying out a randomized,
double-blind, dose-parallel controlled, multicenter Phase II clinical study on
the safety and effectiveness of Gechen Capsule in treating benign prostatic
hyperplasia (turbid blood stasis obstruction syndrome), and now eligible
patients are welcome to participate.
The main components of Gechen Capsule are Pueraria lobata, Pericarpium Citri Tangerinae, Scutellaria baicalensis Georgi, Oyster, Hovenia dulcis Thunb, Talc, etc. This product has the functions of removing blood stasis, resolving stagnation, clearing heat and promoting diuresis, and promoting It has the effect of reducing and controlling prostatic hyperplasia. It is suitable for laborious urination, thinning of urine line, difficulty or impassability of urination, endless urination, frequent urination, urgent urination, frequent nocturnal urination, less abdominal distension, damp scrotum, discomfort of urethra and perineum, etc.
The State Food and Drug Administration has approved the clinical trial of this product (approval number: 2016L03961). The purpose of this paper is to evaluate the safety and effectiveness of Gechen Capsule in treating benign prostatic hyperplasia (turbid blood stasis obstruction syndrome) by observing the effect of Gechen Capsule on narrowing prostate and improving lower urinary tract symptoms and quality of life, and to explore the dose at the same time, so as to provide design basis for the next clinical trial.
Recruitment conditions
1. Conforming to the diagnosis of benign prostatic hyperplasia;
2. It is turbid blood stasis obstruction syndrome under TCM syndrome differentiation;
3. Prostate volume ≥ 30ml (nuclear magnetic resonance method);
4. The age is between 50 and 80 years old (including 50 and 80 years old);
5. The total score of international prostate symptom score is ≥ 7 points and ≤ 19 points;
6. Those who voluntarily participate in this clinical trial, give informed consent and sign informed consent.
Contact:
If you meet all the above requirements and are interested in participating in this research project, please consult our urologist.
Contact person: Mei Qi
Contact: 18056398126
The main components of Gechen Capsule are Pueraria lobata, Pericarpium Citri Tangerinae, Scutellaria baicalensis Georgi, Oyster, Hovenia dulcis Thunb, Talc, etc. This product has the functions of removing blood stasis, resolving stagnation, clearing heat and promoting diuresis, and promoting It has the effect of reducing and controlling prostatic hyperplasia. It is suitable for laborious urination, thinning of urine line, difficulty or impassability of urination, endless urination, frequent urination, urgent urination, frequent nocturnal urination, less abdominal distension, damp scrotum, discomfort of urethra and perineum, etc.
The State Food and Drug Administration has approved the clinical trial of this product (approval number: 2016L03961). The purpose of this paper is to evaluate the safety and effectiveness of Gechen Capsule in treating benign prostatic hyperplasia (turbid blood stasis obstruction syndrome) by observing the effect of Gechen Capsule on narrowing prostate and improving lower urinary tract symptoms and quality of life, and to explore the dose at the same time, so as to provide design basis for the next clinical trial.
Recruitment conditions
1. Conforming to the diagnosis of benign prostatic hyperplasia;
2. It is turbid blood stasis obstruction syndrome under TCM syndrome differentiation;
3. Prostate volume ≥ 30ml (nuclear magnetic resonance method);
4. The age is between 50 and 80 years old (including 50 and 80 years old);
5. The total score of international prostate symptom score is ≥ 7 points and ≤ 19 points;
6. Those who voluntarily participate in this clinical trial, give informed consent and sign informed consent.
Contact:
If you meet all the above requirements and are interested in participating in this research project, please consult our urologist.
Contact person: Mei Qi
Contact: 18056398126
Contact address: Department of Urology, Sandun Hospital, our hospital
